[1] O’Donoghue ML, Vaidya A, Afsal R, et al. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: A collaborative meta-analysis of randomized trials. J Am Coll Cardiol 2012;60:106–111.
[2] Franz-Josef Neumann, Miguel Sousa-Uva, Anders Ahlsson, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2018;00:1–96.
[3]Qi X, Xu M, Yang H, Zhou L, et al. Comparing mortality and myocardial infarction between coronary artery bypass grafting and drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease: a meta-analysis. Arch Med Sci. 2014;10(3):411-8.
[4] Kappetein AP, Head SJ, Morice MC, et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg 2013;43(5):1006-13.
[5] Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 2009;373: 1190–7.
[6] Shah R, Yang Y, Bentley JP, et al. Comparative effectiveness of coronary artery bypass grafting (CABG) surgery and percutaneous coronary intervention (PCI) in elderly patients with diabetes. Curr Med Res Opin 2016;32(11):1891-8.
[7] Brener SJ, Lytle BW, Casserly IP,et al. Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery. Eur Heart J 2006;27:413–418.
[8] Scarsini R, Zivelonghi C, Pesarini G, et al. Repeat revascularization: Percutaneous coronary intervention after coronary artery bypass graft surgery. Cardiovasc Revasc Med 2016;17(4):272-278.
[9] Boyden TF, Nallamothu BK, Moscucci M, et al. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol. 2007;99:1399–402.
[10] Mulukutla SR, Vlachos HA, Marroquin OC, et al. Impact of drug‐eluting stents among insulin-treated diabetic patients: A report from the National Heart, Lung, and Blood Institute Dynamic Registry. JACC Cardiovasc Interv 2008;1:139–147.
[11] Stenestrand U, James SK, Lindbäck J, et al. Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: Long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J2010;31:177–186.
[12] Pendyala LK, Loh JP, Kitabata H, Minha S, et al. The impact of diabetes mellitus on long-term clinical outcomes after percutaneous coronary saphenous vein graft interventions in the drug-eluting stent era. J Interv Cardiol. 2014;27(4):391-8.
[13]Yuichi Nakamura, Yasuhide Asaumi, Tadayoshi Miyagi, et al. Comparison of Long-Term Mortality in Patients with Previous Coronary Artery Bypass Grafting Undergoing Percutaneous Coronary Intervention with Versus Without Optimal Medical Therapy. Am J Cardiol 2018;122:206–212.
[14] Honda S, Asaumi Y, Yamane T, et al. Trends in the clinical and pathological characteristics of cardiac rupture in patients with acute myocardial infarction over 35 years. J Am Heart Assoc 2014;3:e000984.
[15] Moreno PR, Murcia AM, Palacios IF, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000;102:2180–2184.
[16] Marso SP, Mercado N, Maehara A, et al. Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes. JACC Cardiovasc Imaging 2012;5:S42–S52
[17] Schofield I, Malik R, Izzard A, et al. Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation 2002;106:3037-43.
[18] Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
[19] Guandalini GS, Bangalore S. The Potential Effects of New Stent Platforms for Coronary Revascularization in Patients with Diabetes. Can J Cardiol 2018;34(5):653-664.
[20] Scarsini R, Zivelonghi C, Pesarini G, et al. Repeat revascularization: Percutaneous coronary intervention after coronary artery bypass graft surgery. Cardiovasc Revasc Med 2016 ;17(4):272-8.
[21] Baars T, Konorza T, Kahlert P, et al. Coronary aspirate TNF α reflects saphenous vein bypass graft restenosis risk in diabetic patients. Cardiovasc Diabetol 2013;12:12.
[22] Detre KM, Lombardero MS, Brooks MM, et al. The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. Bypass Angioplasty Revascularization Investigation Investigators. N Engl J Med 2000;342(14):989-97.
[23] The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: The Bypass Angioplasty Revascularization Investigation (BARI).Circulation 1997;96:1761–1769.
[24] Tailakh MA, Friger M, Zahger D, et al. Prospective study of the impact of diabetes mellitus newly diagnosed by glycated hemoglobin on outcomes in patients undergoing percutaneous coronary intervention. Eur J Intern Med 2017;37:69-74.
[25] De Luca G, Dirksen MT, Spaulding C, et al. Impact of diabetes on long-term outcome after primary angioplasty: insights from the DESERT cooperation. Diabetes Care 2013;36(4):1020-5..
[26] Wang H, Gao Z, Song Y, et al. Impact of Diabetes Mellitus on Percutaneous Coronary Intervention in Chinese Patients: A Large Single-Center Data. Angiology 2018;69(6):540-547.
[27] Pendyala LK, Loh JP, Kitabata H, et al. The impact of diabetes mellitus on long-term clinical outcomes after percutaneous coronary saphenous vein graft interventions in the drug-eluting stent era. J Interv Cardiol 2014;27(4):391-8.
[28] Ahmed JM, Hong MK, Mehran R, et al. Influence of diabetes mellitus on early and late clinical outcomes in saphenous vein graft stenting. J Am Coll Cardiol 2000; 36(4):1186-93
[29] Ashfaq S, Ghazzal Z, Douglas JS, et al. Impact of diabetes on five-year outcomes after vein graft interventions performed prior to the drug-eluting stent era. J Invasive Cardiol 2006;18(3):100-5.
[30] Coolong A, Baim DS, Kuntz RE, et al. Saphenous vein graft stenting and major adverse cardiac events: A predictive model derived from a pooled analysis of 3958 patients. Circulation 2008;117:790–797.
[31] Brilakis E S , O'Donnell C I , Penny W , et al. Percutaneous Coronary Intervention in Native Coronary Arteries Versus Bypass Grafts in Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. JACC Cardiovasc Interv 2016, 9(9):884-893.
[32] Kereiakes DJ.Reassessing the importance of complete versus incomplete coronary revascularization.Rev Cardiovasc Med 2014,15(1):24-30.